Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS01E adjuvant system
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The AS01E adjuvant system is a liposome-based immunological adjuvant developed by GSK, specifically utilized as a control or comparator in clinical trials for tuberculosis vaccine candidates like M72/AS01E (also known as GSK 692342). It is composed of two key immunostimulants: 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and the saponin QS-21, formulated within a liposomal carrier. MPL is a detoxified derivative of lipopolysaccharide that acts as a Toll-like receptor 4 (TLR4) agonist, while QS-21 is a triterpene glycoside extracted from the bark of the Quillaja saponaria tree that activates the NLRP3 inflammasome. Together, these components synergistically enhance the magnitude and quality of the cellular and humoral immune responses. In the context of tuberculosis research, this adjuvant-only formulation serves as a critical control to differentiate the safety, reactogenicity, and background immunogenicity of the adjuvant system from the effects of the recombinant tuberculosis antigens.
- Other names
- Adjuvant System 01Econtrol vaccine with adjuvant system-GlaxoSmithKline-tuberculosis
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on AS01E adjuvant system.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS01E adjuvant system.